Global Artemisinine Market Size By Type (Extraction from Artemisia annua, Semisynthetic Artemisinine), By Application (Injections, Tablets), By Region, And Segment Forecasts, 2023 to 2032

The Global Artemisinine Market was valued at USD 402.6 million in 2023 and is projected to reach USD 658.3 million by 2031, growing at a CAGR of 6.3% during the forecast period of 2023–2031. Artemisinine, a key component derived from the Artemisia annua plant, plays a crucial role in the treatment of malaria, particularly in artemisinin-based combination therapies (ACTs). Rising malaria prevalence in tropical and subtropical regions, coupled with growing research into the compound’s anti-inflammatory and anticancer properties, is driving market expansion.

Drivers:

1. Rising Incidence of Malaria Globally:

Malaria remains a major public health concern in many developing countries. Artemisinine, being one of the most effective treatments available, has seen increasing demand from public health programs and pharmaceutical manufacturers alike.

2. WHO Endorsement of ACTs:

The World Health Organization's (WHO) recommendation of ACTs as the frontline treatment for Plasmodium falciparum malaria significantly boosts the global demand for artemisinine.

3. Emerging Therapeutic Uses:

Beyond its antimalarial use, ongoing studies exploring artemisinine’s efficacy in treating cancers and autoimmune diseases provide new growth avenues.

Restraints:

1. Seasonal and Geographic Limitations of Cultivation:

Artemisinine is derived from a plant that requires specific growing conditions, making its production vulnerable to environmental factors and limiting scalability.

2. Synthetic Alternatives and Resistance Concerns:

Development of synthetic artemisinine and growing concerns over drug-resistant malaria strains could hinder market growth.

Opportunity:

1. Expansion into Non-Malarial Therapeutics:

Research into the potential of artemisinine in oncology and anti-inflammatory treatment opens untapped markets and could diversify its applications.

2. Increased Government and NGO Funding:

Expanded efforts by global health organizations to eliminate malaria, especially in Sub-Saharan Africa and Southeast Asia, offer significant market potential.

Market by System Type Insights:

By product type, the Artemisinine API segment accounted for the largest market share in 2023. This dominance stems from its widespread use as the active ingredient in the formulation of ACTs. Meanwhile, the Derivatives Segment, including artesunate and artemether, is expected to register notable growth, driven by demand for finished dosage forms in pharmaceutical applications.

Market by End-use Insights:

In terms of end use, the Pharmaceutical Sector led the market in 2023 with over 80% share, fueled by rising ACT consumption. The Research Institutions Segment is also expected to gain traction due to ongoing clinical trials evaluating artemisinine's potential in oncology and virology.

Market by Regional Insights:

Asia-Pacific dominated the market in 2023, supported by China’s role as a major cultivator and producer of Artemisia annua. Africa follows closely due to high malaria prevalence. Meanwhile, North America and Europe are emerging regions due to growing research into the compound's broader therapeutic applications.

Competitive Scenario:

Key market players in the global artemisinine market include Sanofi S.A., Ipca Laboratories Ltd., KPC Pharmaceuticals Inc., Guilin Pharmaceutical Co. Ltd., Calyx Chemicals & Pharmaceuticals Ltd., and Holley Pharmaceutical Co. Ltd. Strategic collaborations, government partnerships, and capacity expansion initiatives remain central to their growth strategies.

Recent Developments:

In 2024, KPC Pharmaceuticals expanded its Artemisia cultivation base in Yunnan Province to increase production capacity.

In 2023, Sanofi announced the renewal of its partnership with the WHO for the supply of ACTs to malaria-endemic countries.

In 2022, Holley Pharmaceutical partnered with a global NGO to distribute low-cost artemisinin-based treatments in Sub-Saharan Africa.

Scope of Work – Global Artemisinine Market

Key Market Developments:

2024: KPC Pharmaceuticals expanded its artemisinine production through local cooperative farming.

2023: Sanofi re-committed to ACT distribution in public-private malaria eradication programs.

2022: Guilin Pharmaceutical launched a pediatric ACT formulation for child malaria patients.

FAQs:

1) What is the current market size of the Global Artemisinine Market?

The Global Artemisinine Market was valued at USD 402.6 million in 2023.

2) What is the major growth driver of the Global Artemisinine Market?

The primary growth driver is the increasing incidence of malaria and widespread adoption of ACTs.

3) Which is the largest region during the forecast period in the Global Artemisinine Market?

Asia-Pacific leads the market due to large-scale production and export of Artemisia annua.

4) Which segment accounted for the largest market share in the Global Artemisinine Market?

The Artemisinine API segment held the largest share in 2023.

5) Who are the key market players in the Global Artemisinine Market?

Key players include Sanofi S.A., Ipca Laboratories Ltd., KPC Pharmaceuticals Inc., and Holley Pharmaceutical Co. Ltd.